<DOC>
	<DOCNO>NCT01756300</DOCNO>
	<brief_summary>The RENABLATE feasibility study prospective , multi-center , non-randomized feasibility study evaluate safety effectiveness investigational multi-electrode ablation catheter integrate ablation system treat resistant hypertension .</brief_summary>
	<brief_title>RENABLATE Feasibility Study CS156 ( EC12-02 ) Study Catheter Based Renal Denervation Treat Resistant Hypertension</brief_title>
	<detailed_description>The RENABLATE feasibility study CS156 ( EC12-02 ) prospective , multi-center , non-randomized feasibility study evaluate safety effectiveness renal artery sympathetic denervation use investigational Celsius® ThermoCool® Renal Denervation ( RD ) Multi-electrode Ablation Catheter integrate ablation system treat resistant hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Renal</mesh_term>
	<criteria>1 . Subject &gt; 18 &lt; 85 year old . 2 . Individual systolic blood pressure ≥ 160 mmHg ( ≥ 150 mmHg type 2 diabetic ) base average 3 office blood pressure reading . 3 . Individual adhere stable drug regimen least 3 different class antihypertensive medication , include diuretic ( change minimum 2 week prior enrollment ) optimal dose expect maintain least 6 month . 4 . Individual agrees study procedure perform , competent willing provide write , inform consent participate study . 1 . Subjects known/diagnosed secondary hypertension . 2 . Subject 'White Coat ' hypertension define 24 hour daytime systolic blood pressure &lt; 135 mm Hg evaluate Baseline visit . 3 . Subject aortoiliofemoral artery anatomy suitable treatment investigational Celsius® ThermoCool® RD Multielectrode Ablation Catheter . 4 . Subject main renal artery &lt; 20 mm length &lt; 4 mm diameter . 5 . Subject multiple main renal artery either kidney . 6 . Subject history prior renal artery intervention include balloon angioplasty , stenting surgery . 7 . Subject previous kidney transplant plan recipient transplant kidney dialysis . 8 . Subject past history unilateral kidney removal solitary functional kidney reason . 9 . Subject estimate glomerular filtration rate ( eGFR ) &lt; 45mL/min/1.73m2 , use MDRD formula . 10 . Subject type 1 diabetes mellitus . 11 . Subject history Myocardial Infarction , unstable angina pectoris , cerebrovascular accident 6 month period prior enrolment , documented widespread atherosclerosis , intravascular thrombosis unstable plaque . 12 . Subject significant surgery cardiovascular intervention 6 month period precede enrollment plan surgery cardiac intervention 6 month period post enrollment . 13 . Subject hemodynamically significant valvular heart disease reduction blood pressure would consider hazardous . 14 . Subject take systemic steroid chronic daily NSAIDs . 15 . Subject know allergy Aspirin and/or procedural drug contrast agent investigator 's opinion exclude him/her study . 16 . Subject serious medical condition , opinion investigator , may adversely affect safety and/or effectiveness participant study ( e.g. , subject active systemic infection , subject clinically significant peripheral vascular disease , abdominal aortic aneurysm , bleed disorder thrombocytopenia , hemophilia , significant anemia ) . 17 . Women childbearing potential positive pregnancy test screening OR woman agree remain birth control followup 6 month OR lactate woman . 18 . Subject know , unresolved history drug use alcohol dependency , lack ability comprehend follow instruction , would unlikely unable comply study followup requirement . 19 . Subject currently enrol another investigational drug device trial .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Essential Hypertension</keyword>
	<keyword>Renal Denervation</keyword>
	<keyword>Vascular Disease</keyword>
	<keyword>Renal Catheter Ablation</keyword>
	<keyword>Primary Hypertension</keyword>
</DOC>